Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency. It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities. Further, the company offers professional services, such as training and certification services, and advanced services. It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel.…
Cellebrite: 3 Key Takeaways for Long-Term Investors
Cellebrite DI (NASDAQ: CLBT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Software - Infrastructure industry, part of the Technology sector, and reports about 1,285 employees.
The shares were at 10.77 USD on 20 November 2026, down 32.6% over 52 weeks. Its 52-week range is 9.580 USD to 19.98 USD: the price is 46.1% below the high and 12.4% above the low.
At a market capitalisation of 2.71B USD, it trades at 43.1 times trailing earnings and 16.1 times forward earnings. The median trailing P/E of its 14 largest Software - Infrastructure peers is 36.9, a premium of 17% for CLBT.
Cellebrite DI reports return on equity of 16.2%, an operating margin of 11.9% and revenue up 18.2% year over year.
It holds more cash than debt, a net cash position of 460.52M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 15.43 USD is 43.3% above the current price. The next earnings report is expected on 10 February 2027.